期刊文献+

脐血CD34^+细胞扩增中系特异性分化抗原的变化 被引量:4

Dynamic of Lineage-Specific Cluster of Differentiation on CD34^+ Cells from Cord Blood during ex vivo Expansion
暂未订购
导出
摘要 目的 :探讨CBCD34 + 细胞扩增的最佳HGF组合及移植时机。方法 :CBCD34 + 细胞培养于无血清培养液中 ,分别加入下列HGF ,A组 :对照组 (无HGF) ;B组 :SCF ,IL 3,IL 6 ;C组 :SCF ,IL 3,IL 6 ,G CSF ,Epo ;D组 :SCF ,IL 3,IL 6 ,TPO ,Flt3 L ;E组 :SCF ,IL 3,IL 6 ,TPO ,Flt3 L ,G CSF ,Epo。培养 2 2d。对不同培养时间的细胞进行NC数量及系特异性CD动态观察。结果 :同对照组相比 ,扩增组NC和CD34 + 细胞均有不同程度的扩增。NC和CD34 + 细胞扩增高峰分别在第 10天和第6天。E组的扩增效果最佳。CD检测显示 ,各组CD34 + 及CD34 + CD38 细胞的比例逐渐减少 ,但B ,D 2组的CD34 + CD38 细胞的比例在第 6天有一过性回升 ,CD14+ ,CD13+ ,CD6 1+ 及Gly A+ 细胞的比例则逐渐升高 ,D组CD34 + 及CD34 + CD38 细胞的比例明显地高于E组 (P <0 .0 1) ,CD3+ 和CD19+ 细胞的比例在扩增中呈下降趋势。结论 :HSPC分化程度与HGF组合及培养时间有关。就细胞总数而言 ,E组HGF组合最佳 ,但就HSPC含量来说 ,以D组为优。第 1周扩增产物中HSPC含量较高 ,移植时间以扩增的第 6~ 10天为宜。 Objective: To explore the optimal combination of HGF for expanding CD34 + cells and the suitable time for transplantation.Methods: CB CD34 + cells were cultured for 22 days in medium containing following combination of HGFs: Group A (Containing no HGFs as control), group B (SCF,IL-3,IL-6), group C (SCF,IL-3,IL-6,G-CSF,Epo),group D (SCF,IL-3,IL-6,TPO,Flt3-L), group E (SCF,IL-3,IL-6,TPO,Flt3-L,G-CSF,Epo). At every intervals, the cells were collected and assayed for CD. Results: NC and CD34 + cells were expanded significantly in all expansion group, the peak of number of NC is on day 10 and that of CD34 + cells is on day 6. The highest level of NC is in group E, and that of CD34 + and CD34 + CD38 - cells is in group D. The content of CD34 + and CD34 + CD38 - cells decreased gradually. Interestingly, the content of CD34 + CD38 - cells in group B and D increased slightly on day 6 and that of CD14 + ,CD13 + ,CD61 + Gly-A + cells elevated increasingly correspondingly. However, the content of CD3 + and CD19 + cells decreased during expansion. Conclusions: Differentiation of CD34 + cells related to combination of HGF and time of ex vivo expansion , SCF combines with IL-3,IL-6,TPO,Flt3-L,G-CSF and Epo is optimal combination regarding to the number of NC, but in view of the content of HSPC, the combination containing SCF,IL-3,IL-6,TPO and Flt3-L is suitable for expansion of HSPC. The content of HSPC reached the highest level in first week, so the suitable time for transplantation of expanded cells is from day 6 to day 10 of expansion.
出处 《中国肿瘤生物治疗杂志》 CAS CSCD 2001年第4期248-252,共5页 Chinese Journal of Cancer Biotherapy
基金 国家"九五"医学科技攻关课题基金 (编号 96 90 6 0 1 17) 国家自然科学基金 (批准号 39870 77) 上海血液学研究所胡应洲基金部分资助
关键词 分化抗原 CD34^+细胞 脐带血 体外扩增 HGF 造血干细胞移植 cluster of differentiation CD34 + cells umbilical cord blood ex vivo expansion
  • 相关文献

参考文献8

  • 1Kayoko Matsumoto,Kazuta Yasui,Naoko Yamashita,et al.in vitro proliferation potential of AC133 positive cells in peripheral blood[J].Stem Cells,2000,18: 196-203.
  • 2Hiroshi Kawada,Kiyoshi Ando,Takashi Tsuji,et al.Rapid ex vivo expansion of human umbilical cord hematopoietic progenitors using a novel culture system[J].Exp Hematol,1999; 27: 904915.
  • 3Rubinstein P,Carrier C,Scaradavou A,et al.Outcomes among 562 recipients of placental -blood transplants from unrelated donors[J].New Engl J Med,1998,339: 1565-1577.
  • 4Cario MS,Wagner JE,Placental and/or umbilical cord blood: An alternative source of hematopoietic stem cells for transplantation[J].Blood,1997,90: 4665-4678.
  • 5唐佩旋.脐带血HSPC移植的基础[C],2000年全国第二届脐血移植和生物学会议论文汇编,16-20.
  • 6Lewis LD,Porada GA,DU JB,et al.Umbilical cord blood cells capable of engrafting in primary,secondary,and tertiary xenogeneic hosts are preserved after ex vivo culture in a noncontact system[J].Blood,2001,97: 3441-3449.
  • 7Andrews RG,Briddell RA,Hill R,et al.Engraftment of primates with G-CSF mobilized peripheral blood CD34 + progenitors cells expanded in G-CSF,SCF and MGDF decreases the duration and severity of neutropenia[J].Stem Cells,1999,17: 210-218.
  • 8Norol F,Drouet M,Mathieu J,et al.ex vivo expanded mobilized peripheral blood CD34 + cells accelerate haematological recovery in a baboon model of autologous transplantation[J].Br J Haematol,2000,109: 162-172.

同被引文献27

  • 1Goodell MA, Rosenzweig M, Kim H, et al. [J]. Natl Med, 1997,3(2) : 1337-1345.
  • 2Zanjiani ED, Almeida-porada G, Livingston AG, et al.[J]. Exp Hematol, 1998,26(1) :353-360.
  • 3Yin All, Miraglia S, Zanjani ED, et al. [J]. Blood, 1997,90(12) :5002.
  • 4Matsumoto K, Yasui K, Yamashita N, et al.[J]. Stem Cells, 2000,18 : 196-203.
  • 5De Wynter EA, Buck D, Hart C, et al. [J]. Stem Cells, 1998,16(6) : 387-396.
  • 6Goussetis E, Theodosaki M, Paterakis G, et al. [J]. J Hematother Stem Cell Res. 2000,9(6) : 827-840.
  • 7Kimum T, Wang JF. [J]. Stem Cells,2000, 18(2):444-452.
  • 8Ueda T,Tsuji K,Yoshino H,et al. [J]. J Clin Invest,2000,105(2) : 1013-1021.
  • 9Egan SE,St Pierre B,Leow CC. [J]. Curt Top Microbiol Immunol, 1998,228 : 273.
  • 10Karanu FN, Murdoch B. Miyabayashi T, et al.[J].Blood, 2001,97(7) : 1960-1967.

引证文献4

二级引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部